Island Pharmaceuticals Limited
Island Pharmaceuticals Limited
Your view on ILA.AX
Overview
What the company does, where it operates, and who runs it.
About Island Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Charles Foster
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Charles Foster
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections.
Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes.
The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach.
Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement.
In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army.
Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Island Pharmaceuticals Limited. Starting points for Island Pharmaceuticals Limited: EPS -AUD 0.03, beta 0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Island Pharmaceuticals Limited. Trailing twelve-month EPS for Island Pharmaceuticals Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2025 | Next quarterJun 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | −AUD 0.01 | −AUD 0.05 | AUD 1.28 |
| Lowest estimate | AUD 0.00 | −AUD 0.01 | −AUD 0.05 | AUD 1.28 |
| Highest estimate | AUD 0.00 | −AUD 0.01 | −AUD 0.05 | AUD 1.28 |
| Number of analysts | 0 | 1 | 1 | 1 |
| A year ago | — | — | −AUD 0.041 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterSep 2025 | Next quarterJun 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 22197.00 | AUD 0.00 | AUD 480.80M | AUD 642.90M |
| Lowest estimate | AUD 22197.00 | AUD 0.00 | AUD 480.80M | AUD 642.90M |
| Highest estimate | AUD 22197.00 | AUD 0.00 | AUD 480.80M | AUD 642.90M |
| Number of analysts | 1 | 0 | 1 | 1 |
| A year ago | — | — | AUD 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| RCE.AXRecce Pharmaceuticals Ltd | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| OCC.AXOrthocell Limited | Healthcare | ASX | — | ||
| OCEAOcean Biomedical, Inc. | Healthcare | PNK | $1.2M | ||
| OCGNOcugen, Inc. | Healthcare | NASDAQ | $250.8M | ||
| OCSOculis Holding AG | Healthcare | NASDAQ | $456.2M | ||
| OCULOcular Therapeutix, Inc. | Healthcare | NASDAQ | $1.3B | ||
| ODTXOdyssey Therapeutics, Inc. | Healthcare | NASDAQ | $912.3M | ||
| OGENOragenics, Inc. | Healthcare | AMEX | $852,760 | ||
| OKUROnKure Therapeutics, Inc. | Healthcare | NASDAQ | $114.2M | ||
| OKYOOKYO Pharma Limited | Healthcare | NASDAQ | $57.7M | ||
| OLMAOlema Pharmaceuticals, Inc. | Healthcare | NASDAQ | $618.5M | ||
| OMEROmeros Corporation | Healthcare | NASDAQ | $1.1B | ||
| ONCBeOne Medicines Ltd. | Healthcare | NASDAQ | $43.1B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Island Pharmaceuticals Limited.